Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 4Lymphoid 3Plasma cell 2

Conditions

Multiple Myeloma 181Recurrence 26Neoplasms, Plasma Cell 16Smoldering Multiple Myeloma 4Neoplasms 4Lymphoma 4Leukemia, Plasma Cell 3Leukemia 2Disease 2Waldenstrom Macroglobulinemia 1Small Cell Lung Carcinoma 1Renal Insufficiency 1Plasmacytoma 1Ovarian Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Myeloid, Acute 1Kidney Neoplasms 1Kidney Failure, Chronic 1Immunoglobulin Light-chain Amyloidosis 1Hodgkin Disease 1Hematologic Neoplasms 1Graft vs Host Disease 1Carcinoma, Non-Small-Cell Lung 1Bone Marrow Neoplasms 1Blast Crisis 1Anemia 1Amyloidosis 1

Interventions

Cyclophosphamide 71fludarabine phosphate 63Busulfan 47Peripheral Blood Stem Cell Transplantation 44Tacrolimus 41Mycophenolic Acid 37Antilymphocyte Serum 37Filgrastim 32Cyclosporine 30Melphalan 29Whole-Body Irradiation 28Radiotherapy 28fludarabine 26Methotrexate 23Methylprednisolone 18Etoposide 18Cord Blood Stem Cell Transplantation 17Rituximab 13Alemtuzumab 13Stem Cell Transplantation 12Granulocyte Colony-Stimulating Factor 10Sirolimus 9Thiotepa 8Cytarabine 8sargramostim 7Prednisone 7Epoetin Alfa 7Flow Cytometry 6thymoglobulin 5Trimethoprim, Sulfamethoxazole Drug Combination 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Leukemia × carfilzomib × Plasma cell × Clear all
NCT03530683 2024-09-03

A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma

Pfizer

Phase 1 Terminated
189 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Multiple Myeloma, Neoplasms, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Neoplasms, Plasma Cell

NCT02145403 2022-01-03

Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies

University of Michigan Rogel Cancer Center

Phase 1/2 Completed
53 enrolled 17 charts
LymphoidOther hematologic neoplasmPlasma cell

Graft vs Host Disease, Leukemia, Lymphoma, Multiple Myeloma, Recurrence, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡